Biomarker Expression in Patients With ACTH-Dependent Cushing's Syndrome Before and After Surgery

Exclusion Criteria

• •Plans for pre-operative and/or intra-operative use of glucocorticoid ("steroid cover").
• •Use any of the following treatments for Cushing's syndrome, as specified:
• •4 weeks prior to first specimen collection and/or during the study period.
• •* Adrenostatic medications (metyrapone, ketoconazole, fluconazole, aminoglutethimide, LCI699 or etomidate etc).
• •* Short-acting somatostatin analogs (octreotide, pasireotide).
• •6 weeks prior to first specimen collection and/or during the study period.
• •o Mifepristone.
• •8 weeks prior to first specimen collection and/or during the study period.
• •o Neuromodulator drugs that act at the hypothalamic-pituitary level: serotonin antagonists (cyproheptadine, ketanserin, retanserin), dopamine agonists (bromocriptine, cabergoline), gamma-aminobutyric acid agonists (sodium valproate), and somatostatin receptor ligands (octreotide long-acting release \[LAR\], pasireotide LAR, lanreotide).
• •Concomitant use of the following due to their potential to stimulate the expression of FKBP5:
• •Testosterone or other steroid hormone analogues.
• •Oral contraceptives or hormonal replacement therapy.
• •History of illness that the Principal Investigator (PI) considers could interfere with or affect the conduct, results, and/or completion of the clinical trial.
• •Pregnancy or breastfeeding.